Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (641-650 of 1,058) with videos related to

Pageof 106
Sort By:
Leukemia|December 17, 2015
Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)B Bhatnagar, J S Blachly, J Kohlschmidt, et al.
Cancer Chemotherapy and Pharmacology|November 19, 2013
A phase I trial of flavopiridol in relapsed multiple myelomaCraig C Hofmeister, Ming Poi, Mindy A Bowers, et al.
British Journal of Haematology|December 2, 2017
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factorKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Blood|January 17, 2004
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsGerard Lozanski, Nyla A Heerema, Ian W Flinn, et al.
Leukemia & Lymphoma|December 22, 2012
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemiaAlison R Walker, Rebecca Klisovic, Jeffrey S Johnston, et al.
Blood|October 22, 2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Haematologica|May 17, 2020
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemiaNyla A Heerema, Natarajan Muthusamy, Qiuhong Zhao, et al.
British Journal of Clinical Pharmacology|January 24, 2019
Population pharmacokinetics of lenalidomide in patients with B-cell malignanciesJim H Hughes, Mitch A Phelps, Richard N Upton, et al.
Journal of Hematology & Oncology|May 3, 2024
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure modelKellie J Archer, Han Fu, Krzysztof Mrózek, et al.
American Journal of Hematology|March 24, 2021
Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasmsMichael Ozga, James Blachly, Ann-Kathrin Eisfeld, et al.
Pageof 106

Showing results (641-650 of 1,058) with videos related to

Sort By:
Pageof 106
Leukemia|December 17, 2015
Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)B Bhatnagar, J S Blachly, J Kohlschmidt, et al.
Cancer Chemotherapy and Pharmacology|November 19, 2013
A phase I trial of flavopiridol in relapsed multiple myelomaCraig C Hofmeister, Ming Poi, Mindy A Bowers, et al.
British Journal of Haematology|December 2, 2017
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factorKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Blood|January 17, 2004
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsGerard Lozanski, Nyla A Heerema, Ian W Flinn, et al.
Leukemia & Lymphoma|December 22, 2012
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemiaAlison R Walker, Rebecca Klisovic, Jeffrey S Johnston, et al.
Blood|October 22, 2009
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Haematologica|May 17, 2020
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemiaNyla A Heerema, Natarajan Muthusamy, Qiuhong Zhao, et al.
British Journal of Clinical Pharmacology|January 24, 2019
Population pharmacokinetics of lenalidomide in patients with B-cell malignanciesJim H Hughes, Mitch A Phelps, Richard N Upton, et al.
Journal of Hematology & Oncology|May 3, 2024
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure modelKellie J Archer, Han Fu, Krzysztof Mrózek, et al.
American Journal of Hematology|March 24, 2021
Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasmsMichael Ozga, James Blachly, Ann-Kathrin Eisfeld, et al.
Pageof 106